66 results
PRE 14A
AXLA
Axcella Health Inc.
7 Aug 23
Preliminary proxy
4:15pm
of Cardiovascular, Renal and Metabolic Diseases Innovative Medicines and Early Development. Dr. Rondinone served in different roles in research and development … biopharmaceutical research and development experience qualifies her to serve on our board of directors.
Paul J. Sekhri has served as a member of our
8-K
EX-99.1
AXLA
Axcella Health Inc.
3 Aug 23
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:04am
million, compared to $17.1 million as of December 31, 2022.
R&D Expenses: Research and development expenses for the quarter and six months ended June 30 … , 2023 were $1.2 million and $2.7 million, respectively. Research and development expenses for the same periods ended June 30, 2022 were $16.9 million
8-K
EX-99.1
yyr889 5ibujwsd3ep
4 May 23
Axcella Reports First Quarter Financial Results and Provides Business Update
4:33pm
8-K
EX-99.1
jwfvwjpxc g5e709
30 Mar 23
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
8:22am
8-K
EX-99.1
p2cu2hm
1 Nov 22
Axcella Reports Third Quarter Financial Results and Provides Business Update
8:02am
424B5
srycrz4g 62
13 Oct 22
Prospectus supplement for primary offering
7:55am
8-K
EX-99.1
m27sayvmyuo21
12 Aug 22
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:11am
8-K
hxxcemr u45mxm
25 May 22
Departure of Directors or Certain Officers
5:01pm
8-K
EX-99.1
ybkn9
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
c89az sf3uari9e
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
424B5
rozwsvqo
16 Mar 22
Prospectus supplement for primary offering
8:00am